Latest Insider Transactions at Uro Gen Pharma Ltd. (URGN)
This section provides a real-time view of insider transactions for Uro Gen Pharma Ltd. (URGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of UroGen Pharma Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of UroGen Pharma Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2020
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
662
-3.25%
|
$12,578
$19.85 P/Share
|
|
Dec 04
2020
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,042
+4.86%
|
-
|
|
Dec 04
2020
|
Elizabeth A. Barrett Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
61,652
+21.96%
|
-
|
|
Oct 26
2020
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
101
-0.52%
|
$2,020
$20.95 P/Share
|
|
Oct 26
2020
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
208
+1.06%
|
-
|
|
Oct 15
2020
|
Peter P. Pfreundschuh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,400
-6.66%
|
$50,400
$21.78 P/Share
|
|
Oct 15
2020
|
Peter P. Pfreundschuh Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,917
+27.75%
|
-
|